1,3-Oxazines as BACE1 and/or BACE2 inhibitors: A patent evaluation (WO2012156284)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 8, 2013, Pages 1069-1073

  Gilbert, Eric J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alzheimer's disease; BACE1; BACE2; Type 2 diabetes

Indexed keywords

1,3 OXAZINE DERIVATIVE; ASPARTIC PROTEINASE INHIBITOR; BETA SECRETASE 1; BETA SECRETASE 1 INHIBITOR; BETA SECRETASE 2; BETA SECRETASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CELL ASSAY; CHEMICAL STRUCTURE; DRUG INDUSTRY; ENZYME INHIBITION; HUMAN; HYPOTHESIS; IC 50; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; REVIEW;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INHIBITORY CONCENTRATION 50; OXAZINES; PATENTS AS TOPIC;

EID: 84880650770     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.818134     Document Type: Review

References (43)

1. Moller HJ, Graeber MB The case described by Alois Alzheimer in 1911 Historical and conceptual perspectives based on the clinical record and neurohistological sections Eur Arch Psychiatry Clin Neurosci 1998;248:111-22
2. Citron M Alzheimer's disease: strategies for disease modification Nat Rev Drug Discov 2010;9:387-98
3. Thies W, Bleiler L 2011 Alzheimer's disease facts and figures Alzheimers Dement 2011;7:208-44
4. Hardy J, Allsop D Amyloid deposition as the central event in the etiology of Alzheimer's disease Trends Pharmacol Sci 1991;12:383-8
5. Hardy JA, Higgins GA Alzheimer's disease: the amyloid cascade hypothesis Science 1992;256:184-5
6. Kung HF The beta-amyloid hypothesis in Alzheimer's disease: seeing is believing ACS Med Chem Lett 2012;3:265-7
7. Walsh DM, Selkoe DJ A beta oligomers-A decade of discovery J Neurochem 2007;101:1172-84
8. De Strooper B, Vassar R, Golde T The secretases: enzymes with therapeutic potential in Alzheimer disease Nat Rev Neurol 2010;6:99-107
9. Available from: ClinicalTrials.gov Indentifier:NCT01739348
10. Available from: ClinicalTrials.gov
11. Available from: ClinicalTrials.gov Identifier:NCT01600859
12. Available from: ClinicalTrials.gov Identifier:NCT01592331
13. Available from: ClinicalTrials.gov Identifier:NCT01795339
14. F Hoffmann-La Roche AG and Siena Biotech S.P.A Preparation of 1,3-oxazines as BACE1 and BACE2 inhibitors WO2012156284A1; 2012
15. F Hoffmann-La Roche AG N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7ahexahydro- cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors WO2013041499A1; 2013
16. F Hoffmann-La Roche AG and Siena Biotech S.P.A Preparation of cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors WO2013004676A1; 2013
17. F Hoffmann-La Roche AG [1,3] Oxazines as BACE inhibitors and their preparation and use as imaging agents and in the treatment of Alzheimer's disease and diabetes WO2012168175A1; 2012
18. F Hoffmann-La Roche AG and Siena Biotech S.P.A Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors and their preparation WO2012168164A1; 2012
19. F Hoffmann-La Roche AG Spiro[1,3] oxazines and spiro[1,4]oxazepines as BACE1 and/or BACE2 inhibitors and their preparation US20120302549A1; 2012
20. F Hoffmann-La Roche AG Preparation of 1,3-oxazines as BACE1 and/or BACE2 inhibitors US20120258962A1; 2012
21. F Hoffmann-La Roche AG and Siena Biotech S.P.A Preparation of 1,4-oxazepines as therapeutic BACE1 and/or BACE2 inhibitors US20120253035A1; 2012
22. F Hoffmann-La Roche AG and Siena Biotech S.P.A 1,4-Oxazepine derivatives asBACE1 and BACE2 inhibitors and their preparation and use for the treatment of Alzheimer's disease and type 2 diabetes US20120238548A1; 2012
23. F Hoffmann-La Roche AG Preparation of 1,4-thiazepines/sulfones as therapeutic BACE1 and/or BACE2 inhibitors US20120225858A1; 2012
24. F Hoffmann-La Roche AG and Siena Biotech S.P.A 1,4-Oxazines as BACE1 and/or BACE2 inhibitors and their preparation US20120184540A1; 2012
25. F Hoffmann-La Roche AG and Siena Biotech S.P.A Preparation of oxazepine derivatives for use as BACE1 and/or BACE2 inhibitors WO2012110459A1; 2012
26. F Hoffmann-La Roche AG Preparation of N-[3-(5-amino-3,3a,7,7a-tetrahydro- 1H-2,4-dioxa-6-azainden-7-yl)phenyl] amides as BACE1 and BACE2 inhibitors US20120202803A1; 2012
27. F Hoffmann-La Roche AG and Siena Biotech S.P.A Preparation of 1,4-oxazines as therapeutic BACE1 and/or BACE2 inhibitors US20120196863A1; 2012
28. F Hoffmann-La Roche AG and Siena Biotech S.P.A Preparation of 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin- 5-ylamine compounds as therapeutic BACE1 and BACE2 inhibitors WO2011138293A1; 2011
29. F Hoffmann-La Roche AG and Siena Biotech S.P.A Preparation of 2-amino-5,5-difluoro-5,6-dihydro-4H-oxazine derivatives as BACE1 and/or BACE2 inhibitors WO2011069934A1; 2011
30. F Hoffmann-La Roche AG and Siena Biotech S.P.A Preparation of 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazine derivatives as therapeutic BACE1 and/or BACE2 inhibitors WO2011020806A1; 2011
31. F Hoffmann-La Roche, Inc and Siena Biotech S.P.A Preparation of 4,4-diphenyl-4,5-dihydro-oxazol-2-ylamine derivatives as beta-secretase inhibitors US20090209529A1; 2009
32. Shionogi & Co., Ltd Preparation of 2-amino-4-phenyl-4,5-dihydro-5H-1, 3-thiazine derivatives and related compounds for treatment of Alzheimer's disease WO2008133273A1; 2008
33. National Diabetes Information Clearinghouse (NDIC) A service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) Available from: http://wwwdiabetes.niddk. nih.gov/dm/pubs/statistics/#fast
34. Akpinar P, Kuwajima S, Krutzfeldt J, et al Tmem27: a cleaved and shed plasma membrane protein that stimulates pancreatic beta cell proliferation Cell Metab 2005;2:385-97
35. Esterhazy D, Stuetzer I, Wang H, et al Bace2 Is a beta cell-enriched protease that regulates pancreatic beta cell function and mass Cell Metab 2011;14:365-77
36. Southan C BACE2 as a new diabetes target: a patent review 2010-2012 Expert Opin Ther Pat 2013;23:649-63
37. Stamford AW, Scott JD, Li SW, et al Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS A-beta reduction ACS Med Chem Lett 2012;3:897-902
38. Hilpert H, Guba W, Woltering TJ, et al beta-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease J Med Chem 2013;56:3980-95
39. Probst G, Xu Y-Z Small-molecule BACE1 inhibitors: a patent literature review (2006-2011) Expert Opin Ther Pat 2012;22:511-40
40. Evin G, Lessene G, Wilkins S BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity Recent Pat CNS Drug Discov 2011;6:91-106
41. Albala B, Kaplow J, Majid O, et al Novel BACE1 Inhibitor E2609 Reduces Plasma and CSF Amyloid in Healthy Subjects after 14 Days Oral Administration AD/PD 2013 The 11th International Conference on Alzheimer's & Parkinson's Diseases; 6-10 March 2013; Eisai, Florence, Italy
42. Palcza J, Tseng J, Dockendorf M, et al The Novel BACE Inhibitor MK-8931 Dramatically Lowers CSF Abeta Peptide in Patients with Mild to Moderate Alzheimer's Disease [Abstract PL02.004] AD/PD 2013, The 11th Annual International Conference on Alzheimer's and Parkinson's Diseases; 6-10 March 2013; Merck, Florence, Italy
43. Willis BA, Komjathy SF, Gonzales CR, et al Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of BACE Inhibitor LY2886721 in Healthy Volunteers (HVs) at Steady State [Abstract P01.017] American Academy of Neurology (AAN) 65th Annual Meeting; 16-23 March 2013; Eli Lilly and Co., San Diego, California